Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Oncogene

• Publication date

  1989-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 2564657
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.

  1988cited by this paper
• In Reply: Amplification c-erbB-2 and Aggressive Human Breast Tumors?

  1988cited by this paper
• Amplification of c-erbB-2 and aggressive human breast tumors?

  1988cited by this paper
• Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion.

  1988cited by this paper
• Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

  1988cited by this paper
• Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene.

  1987cited by this paper
• Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms.

  1987cited by this paper
• Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease.

  1987cited by this paper
• Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene

  1987cited by this paper
• Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer.

  1987cited by this paper
• Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells.

  1987cited by this paper
• erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

  1987cited by this paper
• Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.

  1987cited by this paper
• Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.

  1987cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines.

  1986cited by this paper
• Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor

  1986cited by this paper
• Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

  1986cited by this paper
• Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

  1986cited by this paper
• The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.

  1985cited by this paper
• Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

  1985cited by this paper
• Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

  1985cited by this paper
• A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.

  1985cited by this paper
• Human tumor cell lines with EGF receptor gene amplification in the absence of aberrant sized mRNAs.

  1985cited by this paper
• Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

  1985cited by this paper
• Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

  1984cited by this paper
• Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

  1984cited by this paper
• Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences

  1984cited by this paper
• Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells

  1984cited by this paper
• Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus

  1983cited by this paper
• Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor.

  1983cited by this paper
• Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

  1981cited by this paper
• Identification of epidermal growth factor receptors in a hyperproducing human epidermoid carcinoma cell line.

  1979cited by this paper

• ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

  2025cites this paper
• Features of tumor heterogeneity in regional metastasis of breast cancer

  2021cites this paper
• Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer

  2018cites this paper
• Revieiv Evaluation of HER 2 Status imHuman Breast Carcinoma

  2017cites this paper
• Expression analysis of human epidermal growth factor receptor type 2 transcripts in breast cancer cohort and its association with clinical features.

  2016cites this paper
• Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases

  2016cites this paper
• Comparison Between HER 2 , Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases

  2016cites this paper
• Circulating Tumor Cells in Breast Cancer: Correlation with Clinicopathological Parameters, Hormone Profile and MicroRNA Polymorphisms Comparison of Microvessel Density with Prognostic Factors in Invasive Ductal Carcinomas of the Breast Nasal Polyp – An Incidental Paraganglioma Pulmonary Benign Metas

  2016cites this paper
• Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process

  2015cites this paper
• The Characterization of Anti-HER-2/neu Monoclonal Antibody using Different in vivo Imaging Techniques

  2015cites this paper
• PhD program in Translational and molecular medicine DIMET

  2014cites this paper
• Biomarkers in Breast Cancer and the Implications of Their Discordance

  2013cites this paper
• Advances in Targeting HER3 as an Anticancer Therapy

  2012cites this paper
• Dual-Wavelength Imaging of Tumor Progression by Activatable and Targeting Near-Infrared Fluorescent Probes in a Bioluminescent Breast Cancer Model

  2012influential citation
• Expression of ER/PR/HER2, basal markers and adhesion molecules in primary breast cancer and in lymph nodes metastases: a comparative immunohistochemical analysis.

  2012cites this paper
• Genistein Increases Epidermal Growth Factor Receptor Signaling and Promotes Tumor Progression in Advanced Human Prostate Cancer

  2011cites this paper
• Molecular Medicine in Practice PI 3 K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

  2011cites this paper
• PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

  2011cites this paper
• Classification of Ipsilateral Breast Tumor Recurrences After Breast Conservation Therapy Can Predict Patient Prognosis and Facilitate Treatment Planning

  2011cites this paper
• FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform.

  2011cites this paper
• PI 3 K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

  2011cites this paper
• Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature

  2011cites this paper
• Muc4, the Integral Membrane Modulator of ErbB2:The Effects of Muc4 Expression on ErbB2 and ErbB3 Phosphorylation, Receptor Levels and Sub-Cellular Localization In Breast Cancer Cells Treated With Neuregulin

  2010cites this paper
• Ethanol enhances the interaction of breast cancer cells over-expressing ErbB2 with fibronectin.

  2010cites this paper
• Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance.

  2010cites this paper
• Induction of the Apoptosis Inhibitor ARC by Ras in Human Cancers*

  2010cites this paper
• Immunologische Veränderungen bei Patienten mit akneiformem Exanthem unter Cetuximab-Therapie

  2010cites this paper
• TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.

  2009cites this paper
• Targeting ERBB receptors to inhibit metastasis: old hopes and new certainties.

  2009cites this paper
• Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

  2009cites this paper
• Molecular markers (c-erbB-2, p53) in breast cancer.

  2009cites this paper
• The Impact of ErbB2 on Cancer Progression and Metastasis through Modulation of Tumor and Tumor Microenvironment

  2008cites this paper
• Comparison of Her-2, EGFR and Cyclin D1 in Primary Breast Cancer and Paired Metastatic Lymph Nodes: An Immunohistochemical and Chromogenic In Situ Hybridization Study

  2008cites this paper
• Transforming Growth Factor-/? 1 and 03 mRNA Levels are Associated with ras + myc-induced Carcinomas in Reconstituted Mouse Prostate: Evidence for a Paracrine Role during Progression

  2008cites this paper
• Heregulin‐induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells

  2008cites this paper
• Nuclear factor-K B activation : a molecular therapeutic target for estrogen receptor – negative and epidermal growth factor receptor family receptor – positive human breast cancer

  2007cites this paper
• Why should we still care about oncogenes?

  2007cites this paper
• p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal.

  2007cites this paper
• The effect of chemotherapy on status of estrogen receptors in primary tumors and lymph node metastases of human ductal breast cancer.

  2007cites this paper
• Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.

  2007cites this paper
• Follow-up Study of HER-2/neu Amplification in Primary Breast Cancer1

  2006influential citation
• Stages of Breast Cancer B-2 Gene Copies and Expression in Multiple erb Increased Updated

  2006cites this paper
• Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support.

  2006cites this paper
• Comparison of immunohistological parameters in primary breast cancers and corresponding locoregional recurrences.

  2006cites this paper
• Role of matrix metalloproteinase‐2 in ethanol‐induced invasion by breast cancer cells

  2006cites this paper
• MMP‐2 mediates ethanol‐induced invasion of mammary epithelial cells over‐expressing ErbB2

  2006cites this paper
• Linkage between EGFR family receptors and nuclear factor kappaB (NF‐κB) signaling in breast cancer

  2006influential citation
• Follow-up Study of HER-2 / neu Amplification in Primary Breast Cancer 1

  2006influential citation
• Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma

  2005cites this paper
• Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

  2005cites this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cites this paper
• Nickel(H) induces alterations in EGF- and TGF-prmediated growth control during malignant transformation of human kidney epithelial cells

  2005cites this paper
• An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors

  2004cites this paper
• Enhancement of the p27Kip1‐mediated antiproliferative effect of trastuzumab (Herceptin) on HER2‐overexpressing tumor cells

  2004cites this paper
• Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients

  2004cites this paper
• Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells

  2004influential citation
• Mechanisms of Cancer Chemoprevention by Soy Isoflavone Genistein

  2004cites this paper
• New lead generation strategies for protein kinase inhibitors - fragment based screening approaches.

  2004cites this paper
• erbB-2/Her-2 gene amplification and overexpression in parotid gland tumors

  2004cites this paper
• Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells

  2004cites this paper
• Comparison of Topoisomerase-IIα Gene Status between Primary Breast Cancer and Corresponding Distant Metastatic Sites

  2003cites this paper
• Heregulin and retinoids synergistically induce branching morphogenesis of breast cancer cells cultivated in 3D collagen gels

  2003cites this paper
• Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism.

  2003cites this paper
• Evaluation of HER2 Status in Human Breast Carcinoma

  2003cites this paper
• Targeted therapies in the treatment of pancreatic carcinoma

  2003cites this paper
• Role of Biologic Markers in Patient Selection and Application to Disease Prevention

  2003cites this paper
• General keynote: expression of epidermal growth factor receptor family in transgenic mouse models of human breast cancer.

  2003cites this paper
• CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells.

  2002cites this paper
• A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.

  2002cites this paper
• Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites.

  2002cites this paper
• p185HER‐2/neu and p21CIP1/WAF1 Expression in Primary Tumors and Lymph Node Metastases in Non‐small Cell Lung Cancer

  2002cites this paper
• C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment.

  2002cites this paper
• Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta.

  2002cites this paper
• Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer

  2002cites this paper
• HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

  2002cites this paper
• CD44 Associates With EGFR and erbB2 in Metastasizing Mammary Carcinoma Cells

  2002cites this paper
• EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer.

  2002cites this paper
• Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.

  2002cites this paper
• EGFR and ErbB2 Differentially Regulate Raf-1 Translocation and Activation

  2002cites this paper
• Type 1 Protein Tyrosine Kinases in Breast Carcinoma: A Review

  2002cites this paper
• The N‐terminal domain of SV40 large T antigen represses the HER2/neu‐mediated transformation and metastatic potential in breast cancers

  2002cites this paper
• Mechanism of 17-β-Estradiol-induced Erk1/2 Activation in Breast Cancer Cells

  2002cites this paper
• Mechanisms of action of flavopiridol.

  2001cites this paper
• Type 1 Protein Tyrosine Kinases in Chinese Breast Carcinomas

  2001cites this paper
• A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women.

  2001cites this paper
• HER2/neu as a predictive factor in breast cancer.

  2001cites this paper
• Loss of ErbB2 Expression in Pulmonary Metastatic Lesions in Osteosarcoma

  2001cites this paper
• Assessment of the Activation State of Ras and Map Kinase in Human Breast Cancer Specimens

  2001cites this paper
• P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients.

  2001cites this paper
• Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol.

  2000cites this paper
• Heterogeneity of Cancer Cell Populations and Metastasis

  2000cites this paper
• Ras activation in human breast cancer

  2000cites this paper
• Soy Metabolites, Isoflavones in Cell Growth and Apoptosis

  2000cites this paper
• Study the Pathogenic Role of ErbB-3, ErbB-4 and their Ligand Heregulin in Human Breast Cancer Cells.

  2000cites this paper
• ErbB2 immune response in breast cancer patients with soluble receptor ectodomain.

  2000cites this paper
• Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective.

  2000cites this paper
• Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.

  2000cites this paper
• Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway

  2000cites this paper
• Role of erbB2 in breast cancer chemosensitivity.

  2000cites this paper
• Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle.

  2000cites this paper